Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)

Yazar
Mundle, S.
Li, S.
Luna, Y.
Chi, K.
Ozguroglu, M.
Woo, H.
Fizaz, K.
Sulur, G.
Tran, N.
Fein, L.
Matsubara, N.
Rodriguez-Antolin, A.
Alekseev, B.
Ye, D.
Feyerabend, S.
Protheroe, A.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/12622
Koleksiyonlar